PRN1008

Ex-AbbVie partner Principia posts encouraging PhII results for its BTK-inhibitor
Endpoints
Fri, 10/11/19 - 10:40 am
AbbVie
Principia Biopharma
PRN1008
pemphigus vulgaris
AbbVie, Sanofi-backed Principia offers an $86M IPO after burning through $148M for pipeline work
Endpoints
Mon, 08/20/18 - 10:11 am
IPOs
Principia Biopharma
Sanofi
AbbVie
PRN1008
autoimmune disease